ReviewFrontiers in oncology2017

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers.

Benjamin L Maughan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.